Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial.

ABSTRACT: T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes and NK cells, and is a candidate compensatory immune checkpoint that may mediate anti-PD-1/L1 resistance in hepatocellular carcinoma (HCC). We conducted the phase 2 LIVERTI trial testing domvanalimab, a monoclonal Fc-silent anti-TIGIT antibody, plus zimberelimab, an anti-PD-1 antibody, in immunotherapy refractory HCC. Here, we report an analysis of the primary endpoint, the confirmed overall response rate (ORR). Secondary endpoints included rates of adverse events, progression-free survival (PFS), 6-month PFS survival, overall survival, and duration of response, of which the latter two endpoints were excluded from this analysis due to the immaturity of long-term survival data. Among the 29 pati

SUBMITTER: Hsiehchen D 

PROVIDER: S-EPMC12219336 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature